Clinical Trial Update: A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 3 | Status: RECRUITING